Why you should pay attention to Oncotarget

They cycle between GDO-bound (inactive) and GTP-bound (active).The cycle is controlled by regulatory proteins which they belong to three classes, the guanine nucleotide exchange factors that buffers the exchange of DGP FOR GTP, and guanine nucleotide dissociation inhibitor to form an interconnected compound with GDP and finally the GTPases activating proteins which with addition of water it changes from GTP to GDP.

Oncotarget is a medical journal, reviewed twice weekly. It covers all the stuffs about oncology and even it publishes other topics beyond oncology such as cardiology and neuro science. This journal was developed in 2010 and the impact journals published it. Mikhail Blagoskomy and Andrei Gudkov are the senior editors of this journal. One of its published articles is about a tumor suppressor regulating Rho signaling, The Rho GT pases are responsible functioning such as its polarity, adhesion and apoptosis. Check the journal at SCImago Journal & Country Rank.

When the cells spread and migrates the Rho GTPases it regulates the formation of interconnected compounds, their maturity to adhesion and turning over of these structures along with dynamics of actin cykoskeletal including stress fiber being formed.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget

When the Rho GTPases is dysregulated, it is usually accompanied with abnormal phenotypes which are diverse and abnormal growth of the cells otherwise known as cancer. The tumor suppressor deleted in the cancer of the liver otherwise known as DLCI has been used as an implication for Rho regulator.

DLCI gene translation product is found at the chromosome, an amino acid protein that is equipped with three trans domains that are well recognized; c-terminal steriogenic acute regulatory protein related lipid transfer domain, an N terminal sterile alpha motif and the Rho-GAP domain that is situated upwards from the domain (START). Watch this video on Youtube.

DLCI suppresses tumor and it can be regulated by deletion of genes, point mutations and methylation promoter in a number of cancer found in the human beings such as the prostate cancer, lung cancer, cancer of the colon, breast cancer. If the expression of DLCI is restored it can inhibit the growth of tumor and migrations of the cells to undesired locations.


Integrated Solutions for Patients with the Cancer Treatment Centers of America

The Cancer Treatment Centers of America along with Allscripts, a leader in healthcare information technology, and Nanthealth Inc. taking healthcare to the next level of personalization, together have devised a new way in which doctors can plan and prepare customized healthcare for cancer patients. EvitiĀ® is a clinical decision support solution accessing clinical workflow in Allscripts Sunrise electronic health records (EHR). This clinical operation system, NantOS, was built with a comprehensive collection of cancer care data, creating a network of treatment options for doctors.
As stated in this article, the Clinical Pathways program ingrates new research, average market costs of delivery, and complimentary therapy solutions to build a structure of information in customized patient care. This method will assist in eliminating the guesswork for doctors inundated with new information and create ease individualizing the care of each patient optimizing their quality of life.
This program allows for greater transparency around patient healthcare and assists in building confidence for the patients towards their desired treatment goals. Bringing information regarding new and improved care protocols right to the doctors creates more time efficient planning and integration of patient care. With up to date guidelines, response rates, adverse drug reaction’s and toxicity studies, each doctor can discuss in greater detail with their patients the best treatment options and find the best solution to the patient’s individual needs safely and effectively.
The Cancer Treatment Centers of America have been providing healthcare to adult patients of cancer since 1988. Their national network of five hospitals combine the newest advancements in cancer treatment with individualized patient care.
Their mission is to restore hope and healing to each patient through innovation, respect, and compassion. Working with the patients to heal not just their bodies, but also their hearts and minds through their dedication and devotion to lifelong healing.

For more information follow Cancer Treatment Centers of America on Twitter.

Beau Biden Passes Away After Long Battle With Brain Cancer

The son of Vice President, Joe Biden died on Saturday after a long battle with brain cancer. Joseph ‘Beau’ Biden , known for his military service, political reforms and sound character shocked the nation with his passing. Beau was also known as a democratic superstar as he had a calm demeanor and was a passionate advocate. This 46 year old’s death brings new questions to the front about the disease that killed him.

Doctors use the general term, brain cancer to encompass various benign and malignant tumors that grow around the brain. This disease impacts thousands each year. The past year had almost 70,000 new cases being reported with 14,000 deaths occurring from this disease.

There are many types of brain cancer that occur in adults and they all have a unique features says a scientist from Cubix Latin America. A primary tumor arises from cells that compose the brain itself, a tumor of the skull which covers the brain or a metastatic disease which is when cancer from somewhere else in the body spreads into the central nervous system. They all carry their own prognosis which could be from a life expectancy of eight months to non-life threatening.

It is not known yet which form of brain cancer killed Beau Biden, but it is clear that his treatments to keep it from returning did not work. Often cases like Beau’s turn out to be known as glioblastoma multiforme (GBM). This is an aggressive and very often fatal tumor. What causes these tumors is unknown but it is thought to arise from astrocytes, support cells of the brain. Cases of GBM have been seen to arise from mutations in healthy cells, and some have transformed into GBM from previously existing low grade tumors.

It is not clear what risk factors are associated with the development of GBM. There are some who believe that environmental risks play a big part in them such as radiation from cell phones. This claim is not backed by science. We do know it is a deadly disease and one of the hardest to treat.